Skip to main content

Table 5 Results for the linear mixed model of transformed immunohistochemistry variables

From: Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease

Transformed variable Fixed Effect Phenotype Results for linear mixed model
Beta-coefficient 95% CI
pTau Region x phenotype   1.53* [1.33 – 1.72]
Region Typical AD - 0.82* [- 0.95 – - 0.68]
Atypical AD 0.71* [0.57 – 0.85]
Amyloid-beta Region x phenotype   0.04 [- 0.06 – 0.15]
Region Both - 0.46* [- 0.54 – - 0.39]
GFAP Region x phenotype   1.25* [1.02 – 1.48]
Region Typical AD - 1.71* [- 1.87 – - 1.56]
Atypical AD - 0.46* [- 0.63 – - 0.29]
Iba1 Region x phenotype   0.10 [0.002 – 0.19]
Region Both - 0.47* [- 0.53 – - 0.41]
CD68 Region x phenotype   - 0.43* [0.38 – 0.48]
Region Typical AD - 0.13* [- 0.17 – - 0.10]
Atypical AD 0.29* [0.26 – 0.33]
HLA-DP/DQ/DR Region x phenotype   0.97* [0.88 – 1.06]
Region Typical AD - 0.08* [- 0.14 – - 0.03]
Atypical AD 0.89* [0.82 – 0.96]
C1q Region x phenotype   - 0.05 [- 0.15 – 0.06]
Region Both 0.03 [- 0.05 – 0.10]
C3d Region x phenotype   0.74* [0.62 – 0.86]
Region Typical AD - 0.39* [ - 0.47 – - 0.31]
Atypical AD 0.36* [0.26 – 0.45]
C4b Region x phenotype   0.95* [0.84 – 1.07]
Region Typical AD - 0.24* [- 0.32 – - 0.17]
Atypical AD 0.71* [0.62 – 0.80]
# of amyloid-beta plaques Region x phenotype   0.58* [0.41 – 0.75]
Region Typical AD - 0.33* [- 0.44 – - 0.21]
Atypical AD 0.25* [0.13 – 0.37]
# of C4b plaques Region x phenotype   1.84* [1.58 – 2.11]
Region Typical AD - 0.39* [- 0.56 – - 0.22]
Atypical AD 1.46* [1.25 – 1.66]
  1. Results of the linear mixed model for analyzed immunohistochemistry variables are shown. All variables were transformed: ln(variable + 1). We tested if the distribution over the 2 regions was different between the 2 AD phenotypes, defined as the interaction effect: region × phenotype. When an interaction effect was found, the beta-coefficient is shown per phenotype. To correct for multiple testing, a p value < .0045 was considered significant (p < .05/11 outcome measurements) and indicated with *
  2. AD Alzheimer’s disease, CI confidence interval
  3. # Number